A Novel PDZ Domain Containing Guanine Nucleotide Exchange Factor Links Heterotrimeric G Proteins to Rho*

Shigetomo Fukuhara, Cristina MurgaDagger , Muriel Zohar, Tadashi Igishi, and J. Silvio Gutkind§

From the Oral and Pharyngeal Cancer Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892-4330

    ABSTRACT
Top
Abstract
Introduction
References

Small GTP-binding proteins of the Rho family play a critical role in signal transduction. However, there is still very limited information on how they are activated by cell surface receptors. Here, we used a consensus sequence for Dbl domains of Rho guanine nucleotide exchange factors (GEFs) to search DNA data bases, and identified a novel human GEF for Rho-related GTPases harboring structural features indicative of its possible regulatory mechanism(s). This protein contained a tandem DH/PH domain closely related to those of Rho-specific GEFs, a PDZ domain, a proline-rich domain, and an area of homology to Lsc, p115-RhoGEF, and a Drosophila RhoGEF that was termed Lsc-homology (LH) domain. This novel molecule, designated PDZ-RhoGEF, activated biological and biochemical pathways specific for Rho, and activation of these pathways required an intact DH and PH domain. However, the PDZ domain was dispensable for these functions, and mutants lacking the LH domain were more active, suggesting a negative regulatory role for the LH domain. A search for additional molecules exhibiting an LH domain revealed a limited homology with the catalytic region of a newly identified GTPase-activating protein for heterotrimeric G proteins, RGS14. This prompted us to investigate whether PDZ-RhoGEF could interact with representative members of each G protein family. We found that PDZ-RhoGEF was able to form, in vivo, stable complexes with two members of the Galpha 12 family, Galpha 12 and Galpha 13, and that this interaction was mediated by the LH domain. Furthermore, we obtained evidence to suggest that PDZ-RhoGEF mediates the activation of Rho by Galpha 12 and Galpha 13. Together, these findings suggest the existence of a novel mechanism whereby the large family of cell surface receptors that transmit signals through heterotrimeric G proteins activate Rho-dependent pathways: by stimulating the activity of members of the Galpha 12 family which, in turn, activate an exchange factor acting on Rho.

    INTRODUCTION
Top
Abstract
Introduction
References

The Ras superfamily of GTPases comprises approximately 50 members that can be divided into several families, Ras, Rho, Sar, Rab, Arf, and Ran, based on their primary sequence as well as on their cellular activities (1-3). Whereas the Rab, Arf, and Sar groups participate in the transport of proteins and vesicles among different intracellular compartments, the Ran proteins function in nuclear transport, and Ras plays a central role in cell proliferation and differentiation (2, 4). In the case of Ras, recent studies have revealed how it works at the molecular level. This small GTP-binding protein exchanges GDP for GTP upon activation of Ras-specific guanine nucleotide exchange factors (GEFs)1 (5), and in the GTP-bound state, Ras physically associates with Raf (6) thereby recruiting this serine threonine kinase to the plasma membrane. This causes the activation of Raf and initiates the activity of a sequential cascade of kinases leading to the stimulation of mitogen-activated protein kinases (MAPKs), p42MAPK and p44MAPK, also known as extracellular signal-regulated kinases-2 and -1, respectively, which, in turn, control the activity of nuclear transcription factors that are critical for cell growth (7, 8).

The Rho family of GTP-binding proteins, which consists of the Rho, Rac, and Cdc42 subfamilies, has been shown to regulate several aspects of cytoskeleton function (4). For example, Rho participates in the formation of actin stress fibers and mediates the redistribution of cytoskeletal components (4, 9). Rac is involved in the regulation of lamellipodia (pleat-shaped protrusions at the cell periphery) and membrane ruffling (10); and Cdc42 regulates the formation of thin finger-like cytoplasmic extensions known as filopodia (11). These proteins play an important role in the regulation of cell morphology, cell aggregation, tissue polarity, cytokinesis, cell motility, and also in smooth muscle contraction (12-14). However, recent evidence suggests that Rho proteins are also integral components of signaling pathways leading to transcriptional control. For example, Rac and Cdc42 regulate the activity of the c-Jun amino-terminal kinase (JNK) thereby affecting the transcriptional activity of c-Jun (15), and Rho has been recently shown to induce expression from the serum responsive element (SRE) through the transcriptional activation of the serum response factor (SRF) (16).

The functional activity of small GTP-binding proteins of the Ras superfamily is tightly regulated in vivo by proteins that control their GDP/GTP bound state. Whereas GEFs promote the exchange of GDP for GTP thus activating Ras-like proteins (2), GTPase-activating proteins increase the low intrinsic rate of GTP hydrolysis of small GTPases (reviewed in Ref. 3) and are negative modulators. The mechanisms of activation of GEFs for Ras by cell surface receptors have been intensely investigated. For example, the biochemical route connecting the epidermal growth factor-receptor tyrosine kinase to Ras has been recently identified (5, 17), and includes the phosphorylation of the receptor itself on tyrosine residues, thus creating docking sites for adapter molecules such as Grb2 and Crk. These adapter molecules, in turn, help recruit to the membrane Sos, a Ras-GEF, thereby inducing the exchange of GDP for GTP on Ras. In contrast, the signaling pathway regulating the activity of GEFs for Rho family members is still poorly understood.

Many GEFs for Rho, Rac, and Cdc42, including dbl, ost, lfc, lbc, vav, ect2, tim, and net (reviewed in Refs. 18 and 19) were discovered by virtue of their ability to transform NIH 3T3 cells when overexpressed or when activated by truncations. All these proteins share a 250-amino acid stretch of significant sequence similarity with Dbl, termed Dbl homology (DH) domain, adjacent to a pleckstrin-homology (PH) domain (18, 19). The DH domain was shown to be responsible for nucleotide exchange activity toward GTPases of the Rho family (20, 21). Of interest, one of these GEFs for Rho-like proteins, the protein product of the vav proto-oncogene, proto-Vav, also exhibits a Src homology (SH) 2 domain flanked by two SH3 domains (22, 23), and we have recently shown that tyrosine phosphorylation of proto-Vav by hematopoietic specific tyrosine kinases can activate its GEF activity for Rac both in vitro and in vivo (24, 25). However, no other GEF for Rho-like proteins has been found to be regulated by tyrosine phosphorylation, nor to contain a phosphotyrosine-binding domain such as an SH2 or PTB domains. Furthermore, the vast majority of the known GEFs for small GTP-binding proteins of the Rho family are expressed in a very restricted tissue-specific manner (18, 19), and their mechanism of activation is still largely unknown.

In this study, we explored the existence of novel GEFs for Rho-like proteins possessing structural domains that might suggest a role in signal transduction. Here, we report the identification of a novel, ubiquitously expressed GEF for Rho-like proteins containing a PDZ domain. This protein, termed PDZ-RhoGEF, was found to activate biochemical pathways specific for Rho, in a Rho-dependent manner. Interestingly, PDZ-RhoGEF was found to be closely related to the Drosophila DRhoGEF2, and recent genetic analysis suggests that DRhoGEF2 acts downstream of the concertina gene, a Drosophila Galpha 12 homolog. Here, we found that PDZ-RhoGEF physically associates in vivo with activated alpha  subunits of heterotrimeric G proteins of the G12 family, Galpha 12 and Galpha 13. Association was found to occur through a novel structural domain, termed Lsc homology (LH) domain, located between the PDZ and the DH domain, and also present in the NH2-terminal, regulatory domain of the lsc proto-oncogene product and its human homolog, p115-RhoGEF. This LH domain is distantly related to the G protein-binding region of a family of proteins known as regulators of G protein signaling (RGSs) (26). Together, our present findings suggest the existence of a novel pathway by which the large family of G protein-coupled receptors communicates to Rho through the activation of G12/G13 and the physical association between Galpha 12 or Galpha 13 with LH containing GEFs for Rho, thereby stimulating Rho-dependent pathways.

    EXPERIMENTAL PROCEDURES

Expression Plasmids-- KIAA0380 (human PDZ-RhoGEF), kindly provided by T. Nagase, Kazusa DNA Research Institute, Japan, was subcloned into the pCEFL vector as an Asp718-NotI fragment, thus generating the pCEFL-PDZ-RhoGEF expression plasmid. Then, the coding sequence for the AU1 hexapeptide (DTYRYI) was cloned in-frame with the open reading frame of PDZ-RhoGEF, immediately upstream of the termination codon, thus generating a carboxyl-terminal AU1-tagged PDZ-RhoGEF. cDNAs encoding deletion mutants of PDZ-RhoGEF, as indicated in the corresponding figures, were generated by restriction enzyme digestion or polymerase chain reaction amplification using pCEFL-PDZ-RhoGEF-AU1 as a template. Sequences of mutagenic oligonucleotides will be made available upon request.

Plasmids expressing epitope-tagged MAPK and JNK, pcDNA3 HA-MAPK and pcDNA3 HA-JNK, respectively, as well as expression plasmids for constitutively activated forms of Ras, RhoA, Galpha q, Galpha i2, Galpha s, Galpha 12, and Galpha 13, beta 1 and gamma 2 subunits of G proteins and RhoI41, a RhoA mutant insensitive to the C3 toxin activity, were described previously (15, 27). Reporter plasmids that express the chloramphenicol acetyltransferase (CAT) gene under the control of the wild-type serum response element from the c-fos promoter (SREwt), or a mutant lacking the ternary complex factor-binding site (SREmutL) as well as an expression vector for the C3 toxin were kindly provided by R. Treisman (16).

Northern Blot Analysis-- Human multiple tissue Northern blots, each lane containing 2 µg of poly(A)+ RNA, were purchased from CLONTECH. Total RNA was isolated from several cell lines by RNeasy kit (QIAGEN) according to the manufacturer's instructions, then separated by electrophoresis on a 2% denaturing formaldehyde-agarose gel (20 µg of RNA/lane), and transferred to HybondTM-N nylon membrane (Amersham Life Science). The cDNA probe used for analysis of the PDZ-RhoGEF mRNA was prepared using as a template a 1832-base pair SacI-XbaI fragment derived from pCEFL-PDZ-RhoGEF, containing both 3'-translated and -untranslated regions of PDZ-RhoGEF cDNA. Human beta -actin cDNA (2.0 kilobase pairs) was also used as a control probe. Probes were labeled using a Random Primer DNA labeling kit (Boehringer-Mannheim) with [alpha -32P]dCTP, and RNA hybridization performed as described (28).

Cell Lines and Transfection-- Human kidney 293T cells and COS-7 cells were maintained in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum. NIH 3T3 fibroblasts were maintained in Dulbecco's modified Eagle's medium supplemented with 10% bovine calf serum. 293T cells were transfected by the calcium-phosphate precipitation technique to examine the expression of PDZ-RhoGEF and its mutants or using LipofectAMINE PlusTM reagent (Life Technologies, Inc.) according to the manufacturer's protocol for the co-immunoprecipitation study. Transfection into NIH 3T3 cells were carried out by the calcium-phosphate precipitation technique, and COS-7 cells were transfected by the DEAE-dextran method. In each experiment, total amount of DNA was adjusted to 3-10 µg/plate with vector alone without insert. For the transfection into 293T cells, tissue culture plates were treated with phosphate-buffered saline containing 20 µg/ml poly-D-lysine for 10 min before seeding the cells, to prevent them from detaching from the plates.

Kinase Assays-- MAPK activity in cells transfected with an epitope-tagged MAPK (HA-ERK2, referred in here as HA-MAPK) was determined as described previously (15), using myelin basic protein (Sigma) as a substrate. JNK assays in cells transfected with an epitope-tagged JNK (HA-JNK) was also determined as described previously (15), using purified, bacterially expressed GST-ATF2(96) fusion protein as a substrate. Samples were separated by SDS-gel electrophoresis on 12% acrylamide gels. Autoradiography was performed with the aid of an intensifying screen. Parallel lysates of cells transfected with the HA-MAPK or HA-JNK expression plasmids were processed for Western blot analysis using an antibody against the HA epitope.

Reporter Gene Assays-- NIH 3T3 cells were transfected with different expression plasmids together with 1.0 µg of pCMV-beta gal, a plasmid expressing the enzyme beta -galactosidase, and 1.0 µg of pSREmutL, the reporter plasmid expressing the CAT gene. 293T cells were transfected with expression vectors for PDZ-RhoGEF or its mutants together with 0.5 µg of pCMV-beta gal and 0.5 µg of pSREwt, the reporter plasmid expressing a luciferase gene under the control of the wild-type SRE. After overnight incubation, NIH 3T3 cells and 293T cells were washed twice with phosphate-buffered saline, and kept for approximately 24 h in Dulbecco's modified Eagle's medium supplemented with 0.5% calf serum or 0.5% fetal bovine serum, respectively. Cells were then lysed using reporter lysis buffer (Promega). Additional DNAs were added to the transfection mixtures as indicated in each figure. CAT activity was assayed in the cell extracts by incubation at 37 °C for 10-16 h in the presence of 0.25 µCi of [14C]chloramphenicol (100 mCi/mmol) (ICN) and 200 µg/ml butyryl-CoA (Sigma) in 0.25 M Tris-HCl, pH 7.4. Labeled butyrylated products were extracted using a mixture of Xylenes (Aldrich) and counted as described (15). Luciferase activity in cell extracts was measured using Luciferase assay system (Promega). beta -Galactosidase activity present in each sample was assayed by a colorimetric method, and used to normalize for transfection efficiency.

Immunoprecipitation and Western Blot Analysis-- To confirm the expression of PDZ-RhoGEF and its mutants, 293T cells were transfected with vector or expression vector for each PDZ-RhoGEF-AU1 DNA construct. Then, cells were cultured for 48 h, washed twice with phosphate-buffered saline, and lysed at 4 °C in a buffer containing 25 mM HEPES, pH 7.5, 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM dithiothreitol, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 20 mM beta -glycerophosphate, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml aprotinin, and 20 µg/ml leupeptin. For the co-immunoprecipitation study of PDZ-RhoGEF and heterotrimeric G protein subunits, 293T cells were transfected with vector or expression vector for PDZ-RhoGEF-AU1 or its mutants together with vector or expression vectors carrying cDNAs for the constitutively activated forms of Galpha s Galpha i2, Galpha q, Galpha 12, and Galpha 13 (Galpha sQL, Galpha i2QL, Galpha q QL, Galpha 12QL, and Galpha 13QL, respectively) as well as plasmids expressing beta 1 and gamma 2 cDNAs or epitope-tagged Galpha 12QL and Galpha 13QL (HA-Galpha 12QL and HA-Galpha 13QL, respectively). After culture for 48 h, the cells were washed twice with phosphate-buffered saline, then lysed at 4 °C in 900 µl of lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM MgCl2, 1 mM sodium vanadate, 1% Triton X-100, 10 µM AlCl3, 10 mM sodium fluoride, 20 µg/ml leupeptin, 20 µg/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride), and centrifuged at 15,000 rpm for 10 min at 4 °C. The epitope-tagged PDZ-RhoGEF and its mutants or HA-Galpha 12QL and HA-Galpha 13QL were immunoprecipitated from the cleared lysates by incubation for 1 h at 4 °C with the specific antibody against AU1 or HA, respectively. Immuno complexes were recovered with the aid of Gamma-bind Sepharose beads (Pharmacia).

Lysates and anti-AU1 and anti-HA immunoprecipitates were analyzed by Western blotting after SDS-polyacrylamide gel electrophoresis, transferred to ImmobilonTM-P Transfer Membranes (Amersham Life Science) and immunoblotted with the corresponding rabbit antisera or mouse monoclonal antibody as indicated in each figure. Immuno complexes were visualized by enhanced chemiluminescence detection (Amersham Life Science) using goat anti-rabbit or anti-mouse coupled to horseradish peroxidase as a secondary antibody (Cappel). In this study, we used mouse monoclonal antibodies anti-HA epitope (12CA5, BABCO) and anti-AU1 epitope (BABCO). Polyclonal antiserum to beta  subunits of heterotrimeric G proteins was kindly provided by William Simonds, and anti-Galpha 12/13 rabbit polyclonal serum was described before (29). Rabbit polyclonal antisera to Galpha q and to Galpha s were purchased from Santa Cruz Laboratories and to Galpha i2 from Upstate Biotechnology.

    RESULTS

Identification of a Novel PDZ Domain Containing Guanine Nucleotide Exchange Factor for Rho Proteins-- We set out to identify candidate GEFs for small GTP-binding proteins of the Rho family which contain domains previously implicated in signal transduction. To that end, we searched available DNA data bases using a consensus amino acid sequence derived from the DH domain of known GEFs for Rho-related GTPases (2). This search revealed the existence of a number of yet uncharacterized proteins exhibiting DH-like domains (data not shown). Subsequent analysis of their DNA sequences and their expected translational products suggested that many of them encode putative GEFs for Rho-like proteins. One of them, KIAA0380, accession AB002378, was of particular interest and was further characterized. The corresponding plasmid DNA was obtained from Dr. T. Nagase, Kazusa DNA Research Institute, Japan, and its nucleotide sequence confirmed. Of interest, its open reading frame encodes a protein of 1522 amino acids, possessing areas of high homology to other signaling molecules (Fig. 1A). As depicted in Fig. 1B, this molecule contains a tandem of DH and PH domains, being the DH domain closely related to those of p115-RhoGEF (30) (53% identity, 74% similarity) and Lsc (31) (53% identity, 72% similarity), and to the recently identified DRhoGEF2 (32, 33) (39% identity, 64% similarity). Furthermore, this molecule displays 35% of identity and 45% homology when analyzed for global homology with p115-RhoGEF/Lsc. However, the DH and PH domains were more distantly related to the DH domain of Dbl (20) and PH domain of pleckstrin (34), respectively. This molecule also contains an NH2-terminal region exhibiting extensive homology to a recently identified structural domain termed PDZ (35), which is involved in protein-protein interactions, and is also present in DRhoGEF2. As discussed above, the DH domain is believed to be responsible for the nucleotide exchange activity of GEFs, and both p115-RhoGEF and Lsc have been shown to behave as Rho-specific guanine nucleotide releasing factors (30, 36). Thus, the newly identified molecule, which was tentatively named PDZ-RhoGEF, might represent a novel exchange factor for Rho.


View larger version (75K):
[in this window]
[in a new window]
 


View larger version (77K):
[in this window]
[in a new window]
 
Fig. 1.   PDZ-RhoGEF contains several domains involved in signal transduction and is widely expressed in many human tissues. A, amino acid sequence of PDZ-RhoGEF. The expected translational product of PDZ-RhoGEF, accession number AB002378, is depicted using the 1-letter amino acid code. B, sequence comparison of PDZ-RhoGEF with proteins possessing PDZ, LH, DH, and PH domains. Accession numbers: DRhoGEF2, AF032870; Rhophilin, U43194; GRIP, U88572; Lsc, U58203; p115-RhoGEF, U64105; proto-Dbl, P10911; pleckstrin, P08567. C, Northern blot analysis. A radiolabeled probe encompassing nucleotide sequence corresponding to both 3'-translated and -untranslated regions of PDZ-RhoGEF cDNA (1832 base pairs) was hybridized with poly(A)+ RNA blots prepared from the indicated human tissues. The probe for actin mRNA was hybridized with the same membrane as a control. The arrow indicates the band of actin mRNA.

PDZ-RhoGEF exhibits additional structural features, a proline-rich region (amino acids 149 to 160) and another area (amino acid 290-486) showing a high degree of homology (~34% identity and ~53% similarity) to Lsc, p115-RhoGEF, and DRhoGEF2 (Fig. 1B), that was termed Lsc homology (LH) domain. Thus PDZ-RhoGEF exhibits a number of characteristics that suggest a function in signal transduction: a DH-PH domain highly related to those of Rho GEFs, a PDZ domain, and an area of homology to three other GEFs.

PDZ-RhoGEF Is Widely Expressed-- The majority of the known GEFs for small GTP-binding proteins of the Rho family are expressed in a restricted tissue-specific manner. To investigate the pattern of expression of PDZ-RhoGEF, we performed Northern blot analysis of RNAs from a broad range of human tissues using a non-conserved region including both 3'-translated and -untranslated sequences, nucleotides 3959-5790, of the PDZ-RhoGEF cDNA as a probe. As shown in Fig. 1C, a prominent RNA transcript of approximately 7 kilobases was readily detected in many human tissues, albeit to a different extent. PDZ-RhoGEF is highly expressed in the brain, testis, heart, ovary, and placenta, and to lower levels in kidney, pancreas, spleen, prostate, colon, skeletal muscle, lung, and liver. Whereas no expression was detected in the thymus and small intestine, two RNA species were expressed at comparable levels in peripheral blood leukocytes. The nature of the smaller transcripts detected in leukocytes, as well as that of the additional minor RNA species detected in placenta, spleen, brain, and heart is still unknown, and under current investigation. Similarly, transcripts for PDZ-RhoGEF were detectable in frequently used mammalian cell lines, such as HeLa, 293T, COS-7, and normal human keratinocytes, but limited expression was observed in NIH 3T3 cells (data not shown). Thus, we can conclude that PDZ-RhoGEF is expressed in a large variety of human tissues, rather than in a tissue-restricted manner.

Expression of Wild-type and Truncated Mutants of PDZ-RhoGEF-- To begin exploring the biochemical specificity of PDZ-RhoGEF and the relative contribution of each structural domain, we engineered expression plasmids for epitope-tagged forms of wild-type and truncated PDZ-RhoGEF mutants. Initially, PDZ-RhoGEF was subcloned in an expression vector, pCEFL (37), and then the coding sequence for the hexapeptide DTYRYI was cloned in-frame with the open reading frame of PDZ-RhoGEF immediately upstream of the termination codon, thus generating a carboxyl-terminal AU1-tagged PDZ-RhoGEF. As shown in Fig. 2A, when transfected into 293T cells, wild-type PDZ-RhoGEF was readily detectable with an anti-AU1 epitope-specific antibody. Similarly, each sequential NH2-terminal deletion mutant, Delta -127, Delta -238, Delta -702, and Delta -956, lacking progressively, the PDZ domain, the proline-rich region, the LH domain, and the DH domain, as depicted in Fig. 2A, were also detected in transfected 293T cells.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Activation of the SRE, but not MAPK cascades, by PDZ-RhoGEF. A, structures and expression of epitope-tagged wild type and NH2-terminal truncated mutants of PDZ-RhoGEF. On the left panel, structure of the proteins encoded by each expression plasmid: Delta -127, Delta -238, Delta -702, and Delta -956 constructs code for amino acid residues 127 to 1522, 238 to 1522, 238 to 1522, 702 to 1522, and 956 to 1522 of PDZ-RhoGEF, respectively. On the right panel, lysates from cells transfected with the vector control or with expression plasmid carrying epitope-tagged forms of PDZ-RhoGEF (PDZ-RhoGEF-AU1) and its mutants were immunoprecipitated with anti-AU1 antibody and subjected to Western blot analysis with the antibody to AU1. Bands were visualized by the enhanced chemiluminescence technique using the appropriate horseradish peroxidase-conjugated goat antiserum. B, effects of wild-type and mutant PDZ-RhoGEF on MAPK and JNK activity. COS-7 cells were transfected with pcDNA3-HA-MAPK (1 µg/plate) or pcDNA3-HA-JNK1 (2 µg/plate) for MAPK and JNK assays, respectively, together with pCEFL vector or expression vectors carrying cDNAs for wild-type and NH2-terminal truncated mutants of PDZ-RhoGEF, the mutationally activated Ras (Ras-V12) and onco-Dbl, as indicated (PDZ-RhoGEF and its mutants: 3 µg/plate, Ras-V12 and onco-Dbl: 1 µg/plate). Treatments of cells with 10 µg/ml anisomycin for 20 min or 100 ng/ml 12-O-tetradecanoylphorbol-13-acetate (TPA) for 10 min were used as a control. Kinase reactions were performed in anti-HA immunoprecipitates from the corresponding cellular lysates as described under "Experimental Procedures." Data represent the mean ± S.E. of three independent experiments, expressed as fold increase with respect to vector-transfected cells (vector). Autoradiograms correspond to representative experiments. Western blot (WB) analysis was performed in the corresponding cellular lysates and immunodetected with the antibody to HA. C, effects of wild-type and mutants of PDZ-RhoGEF on the activity of SRE. NIH 3T3 cells were cotransfected with pSREmutL (1 µg/plate) and pCMV-beta -gal (1 µg/plate) plasmid DNAs together with expression vectors carrying cDNAs for wild-type and NH2-terminal truncated mutants of PDZ-RhoGEF (2 µg/plate) or the constitutively activated mutants of Ras and RhoA (1.0 µg/plate), as indicated. Cells were processed as described under "Experimental Procedures." The data represent CAT activity normalized by the beta -galactosidase activity present in each cellular lysate, expressed as fold induction with respect to control cells, and are the mean ± S.E. of triplicate samples from a typical experiment. Similar results were obtained in three separate experiments.

PDZ-RhoGEF Fails to Induce MAPK Cascades-- Whereas Ras controls the MAPK cascade, recent data suggest that Rac and Cdc42 can regulate the activity of the JNK pathway (15). Thus, as an approach to investigate whether PDZ-RhoGEF activates small GTPases of the Ras, Rac, or Cdc42 class, we investigated the ability of PDZ-RhoGEF and its deletion mutants to activate MAPK and JNK in COS-7 cells. As shown in Fig. 2B, none of the PDZ-RhoGEF expression plasmids enhanced the activity of co-transfected HA-MAPK or HA-JNK, although, 12-O-tetradecanoylphorbol-13-acetate addition and activated Ras potently stimulated MAPK, and anisomycin and activated Dbl strongly activated JNK when used as controls under identical experimental conditions. Thus, these data strongly suggest that PDZ-RhoGEF cannot activate Ras and Rac/Cdc42 regulated pathways when expressed in COS-7 cells.

PDZ-RhoGEF Activates SRE in a Rho-dependent Manner-- Recently, Rho proteins have been shown to signal to the SRE through a pathway affecting the transcriptional activity of SRF, independent of any MAPK described to date (16). Thus, we next asked whether PDZ-RhoGEF could induce expression from a reporter plasmid containing a mutated SRE which eliminated the ternary complex factor-binding site and which was shown to be potently activated by Rho (16). As shown in Fig. 2C, an activated form of Rho potently induced expression from this reporter system when used as a control and, under identical experimental conditions, PDZ-RhoGEF caused a remarkable, nearly 15-fold, elevation in CAT activity. Furthermore, whereas deletion of the PDZ and the proline-rich region did not have any demonstrable effect, deletion of the entire NH2-terminal regulatory domain enhanced the ability of PDZ-RhoGEF to stimulate SRF-dependent transcription when expressed at comparable levels. In contrast, as was expected, the deletion mutant lacking also the DH domain failed to elevate CAT expression. Thus, PDZ-RhoGEF potently stimulates SRF-dependent transcription, and that can be enhanced upon deletion of a putative negative regulatory region located between the proline-rich region and the catalytically active DH domain.

As PDZ-RhoGEF induces the expression from an SRE-regulated reporter plasmid, we next explored whether Rho mediates this effect. As an approach, we took advantage of the finding that the botulinum toxin C3 ADP-ribosylates Rho thus preventing its activation (38, 39). As shown in Fig. 3, cotransfection with a C3 toxin expression plasmid abolished the stimulation of CAT activity by the activated, NH2-terminal truncated form of PDZ-RhoGEF. Similar results were obtained using wild-type PDZ-RhoGEF (data not shown). To confirm a role for Rho, we then cotransfected PDZ-RhoGEF and C3 with an expression plasmid for a Rho mutant that is insensitive to the effects of C3, RhoI41 (38, 39). As shown in Fig. 3, RhoI41 restored the ability of PDZ-RhoGEF to stimulate SRE-dependent expression. Taken together, we can conclude that PDZ-RhoGEF potently induces SRE, and that transcriptional stimulation requires a functional Rho protein. In line with these results, we have also found that PDZ-RhoGEF can potently induce the formation of actin stress fibers when expressed in Madin-Darby canine kidney cells, a typical Rho-dependent effect (data not shown). Collectively, these data indicate that PDZ-RhoGEF can effectively activate Rho-dependent pathways.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 3.   Involvement of functional Rho proteins in the SRE activation by PDZ-RhoGEF. NIH 3T3 cells were co-transfected with pSREmutL (1 µg/plate) and pCMV-beta -gal (1 µg/plate) plasmid DNAs and expression vectors for the activated mutant of PDZ-RhoGEF (2 µg/plate, Delta -702), the C3 toxin, and the C3-insensitive mutant of RhoA (5 µg/plate, RhoI41), as indicated. The data represent CAT activity normalized by the beta -galactosidase activity present in each cellular lysate, expressed as fold induction with respect to control cells, and are the mean ± S.E. of triplicate samples from a typical experiment. Similar results were obtained in three independent experiments.

PDZ-RhoGEF Associates Physically with Heterotrimeric G Protein alpha  Subunits of the G12 Family-- A genetic screen for components of the Rho signaling pathway in Drosophila led to the identification of DRhoGEF2, the Drosophila homolog of PDZ-RhoGEF, as an essential molecule for directing cell shape changes associated with gastrulation during early embryo development (32, 33). Of interest, two other molecules were previously identified as critical for gastrulation, folded gastrulation, a secreted protein (40), and concertina, a G protein alpha  subunit related to Galpha 12 (41). Although a direct link between the folded gastrulation receptor, concertina and DRhoGEF2 is yet to be established, these studies suggested that this Rho-GEF might act downstream from heterotrimeric G proteins. Furthermore, a computer assisted search for proteins sharing areas of homology to the LH domain of PDZ-RhoGEF revealed that this domain exhibits limited similarity to a region within the putative catalytic domain of RGS14 (26), a newly discovered RGS for G protein alpha  subunits (Fig. 4). Together, these findings prompted us to explore whether PDZ-RhoGEF could interact directly with a heterotrimeric G proteins.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   Comparison of the amino acid sequences of PDZ-RhoGEF, p115-RhoGEF, and RGS14. The sequences between residues 290 and 486 of PDZ-RhoGEF, residues 25 and 232 of p115-RhoGEF and residues 57 and 235 of RGS14 were optimally aligned on the basis of residue identity (black) and similarity (gray).

As an approach, we co-expressed in 293T cells the AU1-tagged full-length PDZ-RhoGEF together with beta 1gamma 2 dimers or activated forms of representative members of each G protein alpha  subunit family, Galpha q, Galpha s, Galpha i2, and Galpha 12 and Galpha 13 in 293T cells. In each case, we used Galpha proteins rendered constitutively active by replacing a critical glutamine residue within the C3 region that is essential for GTP hydrolysis for leucine (QL mutants) (1). Detailed biochemical characterization of each G protein subunit has been previously reported in our laboratory (29, 42-45). As shown in Fig. 5A, the tagged PDZ-RhoGEF and all transfected G protein alpha  subunits and beta gamma heterodimers were expressed, as judged by Western blot analysis using anti-epitope monoclonal antibodies and G protein subtype-specific antisera. Surprisingly, we found that when PDZ-RhoGEF was immunoprecipitated, both members of the Galpha 12 family, Galpha 12 and Galpha 13, co-immunoprecipitated with this putative nucleotide exchange factor for Rho. No other G protein subunit was found to co-immunoprecipitate with PDZ-RhoGEF, nor were Galpha 12 and Galpha 13 detectable in immunoprecipitates from control samples (Fig. 5A). To confirm these findings, we co-expressed the AU1-tagged PDZ-RhoGEF with NH2-terminal HA-tagged forms of Galpha 12 and Galpha 13, and performed anti-AU1 and anti-HA Western blots on both anti-HA and anti-AU1 immunoprecipitates. As shown in Fig. 5B, the activated forms of Galpha 13 efficiently co-immunoprecipitated PDZ-RhoGEF. Similar results were obtained with Galpha 12, although the co-immunoprecipitation of PDZ-RhoGEF was less efficient because the HA-tagged Galpha 12 was poorly expressed (data not shown). We concluded that both members of the Galpha 12 family physically associate in vivo with PDZ-RhoGEF, thus providing a direct link between heterotrimeric G proteins and small GTP-binding proteins of the Ras superfamily.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 5.   Direct interaction of PDZ-RhoGEF with heterotrimeric G protein alpha  subunits of the G12 family. A, 293T cells were transfected with vector or expression vector (C) for PDZ-RhoGEF-AU1 (P-AU1) together with vector or expression plasmids carrying cDNAs for the constitutively activated mutants of Galpha s, Galpha i2, Galpha q, Galpha 12, and Galpha 13 as well as plasmids expressing beta 1 and gamma 2 cDNAs, as indicated. Lysates, prepared as described under "Experimental Procedures," were immunoprecipitated (IP) with anti-AU1 antibody and subjected to Western blot (WB) analysis using anti-AU1 antibody and G protein subtype-specific antisera. In addition, total cellular lysates (TCL) were subjected to Western blot analysis with G protein subtype-specific antisera. B, lysates from cells transfected with vector or expression plasmids for PDZ-RhoGEF-AU1 together with vector or expression vectors carrying cDNAs for an epitope-tagged and activated form of Galpha 13 (HA-Galpha 13QL) were immunoprecipitated with anti-AU1 and anti-HA antibody, and were subjected to Western blot analysis with antibodies to HA and AU1, respectively. In addition, total cellular lysates were used in Western blot analysis with anti-AU1 and anti-HA antibodies. Bands were visualized by the enhanced chemiluminescence technique using the appropriate horseradish peroxidase-conjugated goat antiserum. In this figure, Galpha , AU1, and HA are used for abbreviations anti-Galpha antiserum, anti-AU1 antibody, and anti-HA antibody, respectively.

PDZ-RhoGEF Binds Heterotrimeric G Proteins through a Novel Structural Domain Designated LH-- To investigate further the identity of the structural domains of PDZ-RhoGEF involved in binding to Galpha 12 and Galpha 13, we used the progressive truncated forms of PDZ-RhoGEF described above, lacking the PDZ domain (Delta -127), the PDZ domain, and the proline-rich domain (Delta -238), and the entire NH2-terminal regulatory region (Delta -702). We also engineered additional deletion mutants, lacking the LH domain (Delta LH), the PH domain (Delta PH), and the DH/PH domain (Delta DH/PH), as depicted in Fig. 6A. All deletion mutants were efficiently expressed when transfected into 293T cells (see above and Fig. 6A). However, when co-expressed with an activated epitope-tagged form of Galpha 12 and Galpha 13, we found that all PDZ-RhoGEF deletion mutants lacking the LH domain were unable to associate in vivo with these G protein alpha  subunits (Fig. 6B). These data indicate that the ability of PDZ-RhoGEF to bind heterotrimeric G proteins of the Galpha 12 family is strictly dependent upon the structural integrity of its LH domain.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 6.   Interaction of PDZ-RhoGEF with heterotrimeric G protein alpha  subunits through the LH domain. A, structure and expression of deletion mutants of PDZ-RhoGEF. Structure of the proteins encoded by the expression plasmids used in this figure are shown (left and in Fig. 2A). Delta -LH, Delta -PH, and Delta -DH/PH constructs, lacking LH, PH, and both DH and PH domains, respectively, codes for amino acid sequences in which residues 171-484, 956-1054, and 738-1054 were deleted from PDZ-RhoGEF, respectively. Lysates from cells transfected with vector or with expression plasmid carrying an epitope-tagged PDZ-RhoGEF (PDZ-RhoGEF-AU1) and its deletion mutants were immunoprecipitated with anti-AU1 antibody and these immunoprecipitates were subjected to Western blot analysis with the antibody against AU1. B, 293T cells were transfected with vector or expression plamids for Galpha 12QL or Galpha 13QL together with vector or expression vectors carrying cDNAs for wild type and deletion mutants of PDZ-RhoGEF, as indicated. Lysates, prepared as described under "Experimental Procedures," were immunoprecipitated with anti-AU1 antibody and subjected to Western blot (WB) analysis using specific antiserum for heterotrimeric G proteins of the G12 family. Total cellular lysates (TCL) were also subjected to Western blot analysis using the same antiserum. In A and B, bands were visualized by the enhanced chemiluminescence technique using the appropriate horseradish peroxidase-conjugated goat antiserum. C, effects of wild-type and deletion mutants of PDZ-RhoGEF on the activity of the SRE. NIH-3T3 cells were co-transfected with pSREmutL (1 µg/plate) and pCMV-beta -gal (1 µg/plate) plasmid DNAs together with expression vectors carrying cDNAs for wild-type and deletion mutants of PDZ-RhoGEF, as indicated. Cells were processed as described under "Experimental Procedures." The data represent CAT activity normalized by the beta -galactosidase activity present in each cellular lysate, expressed as fold induction with respect to control cells, and are the mean ± S.E. of triplicate samples from a typical experiment. Similar results were obtained in three independent experiments.

To further study the role of the LH domain in signaling, we investigated the ability of each deletion mutant to activate SRE, a Rho-dependent event. As shown in Fig. 6C, the PH and DH domains are strictly required to induce SRE, and as described above, deletion of the PDZ and PDZ + proline-rich domains did not affect the ability of PDZ-RhoGEF to stimulate SRE. However, deletion of the entire NH2-terminal regulatory region or the LH domain enhanced the activity of PDZ-RhoGEF. Thus, these data strongly suggest that the NH2-terminal regulatory region exerts a negative regulatory activity on the catalytic DH/PH domains, and that the LH domain may be responsible for this inhibitory activity.

A DH and PH Deletion Mutant of PDZ-RhoGEF Prevents Signaling from Galpha 12 and Galpha 13 to Rho-dependent Pathways-- The availability of biochemically inactive PDZ-RhoGEF mutants prompted us to ask whether they can affect signaling from Galpha 12 and Galpha 13 to SRE, a Rho-dependent event (27). For these experiments, we chose to use 293T cells as the transfection efficiency in these cells is greater than that in NIH 3T3 cells, thus allowing us to control the expression of each transfected DNA construct. As shown in Fig. 7, expression in 293T cells of PDZ-RhoGEF lacking the DH/PH domains or the entire NH2-terminal region + DH domain (Delta -956) did not affect SRE activation by RhoQL, when used as a control. In contrast, the PDZ-RhoGEF DH/PH deletion mutant specifically blocked SRE activation by Galpha 12 and Galpha 13. Similarly, this PDZ-RhoGEF mutant diminished the activation of SRE when mediated by lysophosphatidic acid receptors (data not shown). Thus, PDZ-RhoGEF Delta DH/PH behaves as a dominant negative mutant, probably by preventing the coupling of Galpha 12 and Galpha 13 to the endogenously expressed PDZ-RhoGEF or to other related GEFs.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 7.   Inhibition of Galpha 12- and Galpha 13-mediated SRE activation by the DH and PH deletion mutant of PDZ-RhoGEF. 293T cells were cotransfected with pSREwt (0.5 µg/plate) and pCMV-beta -gal (0.5 µg/plate) plasmid DNAs together with expression vectors carrying cDNAs for the constitutively activated mutants of Galpha 12, Galpha 13, and RhoA, Delta -DH/PH, Delta -956, and green fluorescent protein (GFP) (control), as indicated. Cells were processed as described under "Experimental Procedures." The data represent luciferase activity normalized by the beta -galactosidase activity present in each cellular lysate, expressed as a percentage relative to that observed in control, and are the mean ± S.E. of triplicate samples from a typical experiment. Similar results were obtained in three independent experiments.


    DISCUSSION

Although small GTP-binding proteins of the Rho family play a critical role in a variety of cellular functions, including the organization of the actin cytoskeleton and the activity of biochemical routes regulating gene expression and cell growth, how these GTPases are activated by cell surface receptors is still largely unknown. Thus, we investigated whether novel exchange factors for Rho-related GTPases might exist, exhibiting functional domains suggestive of a role in signal transduction. For this, we took advantage of the observation that all known GEFs for Rho proteins exhibit a DH domain, a 250-amino acid stretch of significant sequence similarity to Dbl, a transforming protein that was originally isolated from a diffuse B cell lymphoma (46). Using a consensus sequence for DH domains of Rho-exchange factors (2) to search DNA data bases, we identified a yet uncharacterized molecule exhibiting a putative DH domain. Detailed analysis of its primary sequence revealed that this molecule contained additional areas of similarity with known modular domains, including a PH domain, a PDZ domain, a proline-rich region, and an area of homology to p115-RhoGEF, DRhoGEF2 and Lsc, that was not found in any other GEF described so far, and that was termed LH domain. As many of these protein regions are likely candidates to participate in signal transmission, we decided to investigate further this novel putative exchange factor.

When the DH domain of this new molecule was compared with those of other DH containing proteins, we found that it was highly related to that of two Rho-specific GEFs, p115-RhoGEF (30) and Lsc (31), and to a recently described Drosophila Rho GEF, DRhoGEF2 (33). However, PDZ-RhoGEF was more distantly related to the DH domain of exchange factors activating Rac1 and/or Cdc42 such as Tiam1 (47), Vav (48), Ost (49), and Dbl (46), and to those acting on Ras, including Sos (50) and Ras-GRF (51). Consistent with this observation, expression of epitope-tagged forms of this novel GEF did not elevate the activity of co-transfected HA-tagged forms of MAPK and JNK, but potently stimulated the transcriptional activity of SRF, as judged by the use of a reporter plasmid under the control of a mutated SRE (16). Furthermore, experiments with the use of botulinum C3 exoenzyme, which ADP-ribosylates and inactivates Rho, and an inactivation resistant form of Rho, RhoI41, indicated that the enhanced expression from the SRE-driven plasmid was dependent on the availability of a functional Rho. In addition, we have recently observed that expression of this molecule in Madin-Darby canine kidney cells potently induces the formation of actin stress fibers, to an extent comparable to that caused by expressing activated forms of Rho.2 Thus, taken together, the primary sequence similarity with Rho GEFs and these biochemical profiles strongly suggest that this novel DH-containing molecule, that was designated PDZ-RhoGEF, can stimulate in vivo Rho-specific pathways.

In addition to the DH domain, a PH domain is present in all GEFs for Rho-related proteins described so far, located adjacent to the carboxyl end of the DH domain (18). PH domains are found in a wide variety of signaling molecules (52) and have been implicated in both protein-protein and protein-lipid interactions (53). Although a DH domain is necessary and sufficient for the exchange activity on Rho proteins in vitro (20), the integrity of the PH domain is required for the activity in vivo of this family of exchange factors (31) most likely by facilitating membrane translocation (31). Consistent with those observations, deletion of the DH domain, PH domain, or DH/PH domains abolished the biochemical activity of PDZ-RhoGEF. Similarly, PDZ-RhoGEF readily induced the appearance of foci of transformation when expressed in NIH 3T3 cells, and this activity required the presence of an intact DH and PH domain (data not shown), supporting a critical role for the DH and PH domains for the functional activity of PDZ-RhoGEF.

The most striking feature of this novel exchange factor was the presence of a PDZ domain, a protein-protein interaction domain originally identified as an area of homology between the product of the Drosophila dlg tumor suppresor gene and the synaptic protein PSD-95 (54), currently found in more than 60 distinct gene products (35). These domains can either bind specific recognition sequences such as the (S/T)XV motif at the carboxyl termini of certain proteins, or they can form hetero- or homodimers, suggesting that this modular protein-binding domain can participate in the formation of macromolecular complexes (35). Thus, the PDZ domain was expected to contribute to PDZ-RhoGEF function. Surprisingly, however, when this domain was deleted, we did not observe any demonstrable effect on the ability of PDZ-RhoGEF to induce Rho-dependent pathways. Similarly, deletion of the PDZ domain was shown not to affect the biological activities of the Rac1 exchange factor Tiam1 (55). Although, based on these results, we cannot rule out the possibility that the PDZ domain facilitates the interaction of PDZ-RhoGEF and other exchange factors with yet to be identified signaling molecules (see below), we therefore decided to focus our efforts on other putative functional domains. One such interesting domain is a stretch of 197 amino acids located upstream from the DH domain, that was termed LH domain for Lsc homology domain, and that is also found in Lsc, p115-RhoGEF, and DRhoGEF2 but not in any other GEF. This suggests that the LH domain represents a distinctive feature of this subgroup of exchange factors, which might bear functional relevance. Indeed, deletion of the LH domain enhanced the ability of PDZ-RhoGEF to stimulate SRE, to an extent comparable to that of a truncation mutant lacking the entire NH2-terminal regulatory region. Similarly, we found that NH2-terminal truncated or LH-deleted forms of PDZ-RhoGEF exhibit enhanced focus forming activity in NIH 3T3 cells when compared with the wild-type form.3 Thus, PDZ-RhoGEF, like other GEFs, appears to be negatively regulated by inhibitory sequences within the non-catalytic region (18), and this inhibitory function most likely resides in the LH domain.

Because of the possibility that the LH domain might have a regulatory function, we searched data bases for molecules displaying sequences related to the LH domain. Surprisingly, we found that the catalytic region of a recently described GTPase-activating proteins for heterotrimeric G proteins, RGS14, exhibited a limited sequence similarity to the LH domain. RGSs were initially identified as homologues of Sst2 proteins, which are negative regulators of pheromone signaling in yeast (56). This protein family, currently with 19 members, shares a 120-amino acid core, termed GH domain, which is essential for accelerating the rate of GTP hydrolysis on Galpha proteins (56). RGS14, together with RGS12, represent novel members of this family, characterized for being substantially larger (~60 and ~140 kDa, respectively) than the majority of the other known RGSs (~25 kDa) (26). This data suggested that the LH domain might confer to PDZ-RhoGEF the ability to interact with G protein alpha  subunits. Indeed, we found that PDZ-RhoGEF could form stable complexes in vivo specifically with members of the G12 family of G protein alpha  subunits, Galpha 12 and Galpha 13, and that this interaction required the presence of an intact LH domain. Taken together, we can conclude that PDZ-RhoGEF can interact physically with a particular subset of Galpha proteins, thereby providing a direct link between hetereotrimeric G proteins and small GTP-binding proteins of the Rho family.

These findings may have important implications regarding the function of G proteins of the G12 family, Galpha 12 and Galpha 13. These ubiquitously expressed G proteins were discovered by M. Simon's group upon amplification of mouse brain cDNA by polymerase chain reaction using degenerated oligonucleotides corresponding to regions highly conserved among G proteins (57). Galpha 12 and Galpha 13 exhibit 67% amino acid identity with each other, but only 35-44% of amino acid identity to alpha  subunits of other classes, such as Gq, Gi, and Gs (57). Furthermore, whereas members of the Galpha q family of G proteins activate phosphatidylinositol-specific phospholipases, the Galpha s family stimulate adenylyl cyclases, and Galpha i inhibits adenylyl cyclases and activate certain phosphodiesterases and promote the opening of several ion channels (58-60), members of the Galpha 12 family of GTPases appear not to affect any of these second messenger-generating systems (60). In this regard, the finding that concertina (cta), a Drosophila gene involved in embryogenesis (41), and that Galpha 12 and Galpha 13 can behave as remarkably potent oncogenes (29, 42), provided early indications that this G protein class might be involved in growth regulation, albeit through poorly defined mechanisms. Intense investigation in many laboratories has recently generated a wealth of information on how Galpha 12 and Galpha 13 may act (see Ref. 61, for a recent review). In particular, one such study (62) demonstrated that activated Galpha 12 and Galpha 13, but not Galpha i2 and Galpha q or different combinations of beta  and gamma  subunits, mimicked the effect of activated RhoA on stress fibers and focal adhesion assembly, and we have recently provided evidence that Galpha 12 stimulates nuclear responses and cellular transformation through Rho (27). Furthermore, several studies have now provided evidence that members of the G12 family of G proteins link many G protein-coupled receptors, including receptors for lysophosphatidic acid, thrombin, thromboxane A2, and acetylcholine to the activation of Rho-dependent pathways and, in many cases, cell growth control (27, 63-66).

However, the nature of the molecules linking Galpha 12 and Galpha 13 to Rho remained largely unknown. In this regard, our present results suggest that PDZ-RhoGEF or other LH-containing RhoGEF might act downstream from these G protein alpha  subunits in a biochemical route leading to Rho activation (see Fig. 8). Moreover, while our study was in the process of submission, it was reported that Galpha 13 could enhance the in vitro Rho-GEF activity of p115-RhoGEF, a distinct LH domain-containing exchange factor (67, 68). However, how the interaction between RhoGEFs and Galpha 12 and/or Galpha 13 leads to Rho activation in vivo is still unclear. For PDZ-RhoGEF, it is possible that binding of G12 proteins to its LH domain results in the translocation of PDZ-RhoGEF to the membrane where it can act on Rho. Alternatively, binding of G12 to the LH domain might de-repress the functional activity of PDZ-RhoGEF by preventing its negative modulatory effect. In addition, although the functional significance of the PDZ domain is still unclear, it is noticeable that some receptors known to induce Galpha 12 and activate Rho exhibit a COOH-terminal PDZ-binding motif, such as SVV in the case of both human and murine lysophosphatidic acid receptors, EDG-2 and VZG-1, respectively (69, 70). Thus, it is also possible that certain G12-coupled receptors might facilitate the recruitment of PDZ-RhoGEF by binding to its PDZ domain and, simultaneously, activating G12 proteins. These, as well as other possibilities, are under current investigation.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 8.   Proposed mechanism whereby G-protein coupled receptors stimulate Rho-dependent pathways. The stimulation of certain G protein-coupled receptors activates Galpha 12 and Galpha 13 which, in turn, interact with PDZ-RhoGEF through its LH domain, thereby causing the activation of PDZ-RhoGEF by a still unclear mechanism. Subsequently, the activated PDZ-RhoGEF catalyzes the exchange of GDP for GTP on Rho through its DH and PH domains, leading to the activation of Rho-dependent pathways. Additional possibilities are also discussed in the text.

We can conclude that our present findings support the existence of a novel mechanism whereby the large family of G protein-coupled cell surface receptors can stimulate Rho-dependent pathways (Fig. 8). This pathway involves the activation of Galpha 12 and/or Galpha 13, which, in turn, will interact directly with Rho-exchange factors containing a Galpha 12/Galpha 13-binding region, such as an LH domain. This would result in the activation of Rho by a still unclear mechanism, thereby stimulating the activity of Rho-dependent pathways that, ultimately, would affect the cytoskeletal structure, nuclear gene expression, and cellular growth.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a postdoctoral fellowship from the Spanish Ministerio de Educación y Cultura.

§ To whom correspondence should be addressed: Oral and Pharyngeal Cancer Branch, NIDCR, National Institutes of Health, 30 Convent Dr., Bldg. 30, Rm. 212, Bethesda, MD 20892-4330. Tel.: 301-496-6259; Fax: 301-402-0823; E-mail: gutkind{at}nih.gov.

2 M. Zohar and J. S. Gutkind, unpublished data.

3 S. Fukuhara and J. S. Gutkind, unpublished results.

    ABBREVIATIONS

The abbreviations used are: GEF, guanine nucleotide exchange factor; LH domain, Lsc homology domain; MAPK, mitogen-activated protein kinase; JNK, c-Jun amino-terminal kinase; SRE, serum response element; SRF, serum response factor; GAP, GTPase-activating protein; DH domain, Dbl homology domain; PH domain, pleckstrin-homology domain; SH, Src homology; RGS, regulators of G protein signaling; CAT, chloramphenicol acetyltransferase.

    REFERENCES
Top
Abstract
Introduction
References
  1. Bourne, H. R., Sanders, D. A., and McCormick, F. (1991) Nature 349, 117-27[CrossRef][Medline] [Order article via Infotrieve]
  2. Boguski, M. S., and McCormick, F. (1993) Nature 366, 643-654[CrossRef][Medline] [Order article via Infotrieve]
  3. Lamarche, N., and Hall, A. (1994) Trends Genet. 10, 436-440[CrossRef][Medline] [Order article via Infotrieve]
  4. Hall, A. (1994) Annu. Rev. Cell Biol. 10, 31-54[CrossRef]
  5. Schlessinger, J. (1993) Trends Biochem. Sci. 18, 273-275[CrossRef][Medline] [Order article via Infotrieve]
  6. Marshall, M. (1995) Mol. Reprod. Dev. 42, 493-499[Medline] [Order article via Infotrieve]
  7. Davis, R. J. (1993) J. Biol. Chem. 268, 14553-14556[Free Full Text]
  8. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726-735[Abstract/Free Full Text]
  9. Ridley, A. J., and Hall, A. (1992) Cell 70, 389-399[Medline] [Order article via Infotrieve]
  10. Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) Cell 70, 401-410[Medline] [Order article via Infotrieve]
  11. Tapon, N., and Hall, A. (1997) Curr. Opin. Cell Biol. 9, 86-92[CrossRef][Medline] [Order article via Infotrieve]
  12. Hotchin, N. A., and Hall, A. (1996) Cancer Surv. 27, 311-322[Medline] [Order article via Infotrieve]
  13. Narumiya, S., Ishizaki, T., and Watanabe, N. (1997) FEBS Lett. 410, 68-72[CrossRef][Medline] [Order article via Infotrieve]
  14. Narumiya, S. (1996) J. Biochem. (Tokyo) 120, 215-228[Abstract]
  15. Coso, O. A., Chiariello, M., Yu, J. C., Teramoto, H., Crespo, P., Xu, N., Miki, T., and Gutkind, J. S. (1995) Cell 81, 1137-1146[Medline] [Order article via Infotrieve]
  16. Hill, C. S., Wynne, J., and Treisman, R. (1995) Cell 81, 1159-1170[Medline] [Order article via Infotrieve]
  17. Marshall, C. J. (1995) Cell 80, 179-185[Medline] [Order article via Infotrieve]
  18. Whitehead, I. P., Campbell, S., Rossman, K. L., and Der, C. J. (1997) Biochim. Biophys. Acta 1332, F1-F23[CrossRef][Medline] [Order article via Infotrieve]
  19. Van Aelst, L., and D'Souza-Schorey, C. (1997) Genes Dev. 11, 2295-2322[Free Full Text]
  20. Hart, M. J., Eva, A., Zangrilli, D., Aaronson, S. A., Evans, T., Cerione, R. A., and Zheng, Y. (1994) J. Biol. Chem. 269, 62-65[Abstract/Free Full Text]
  21. Hart, M. J., Eva, A., Evans, T., Aaronson, S. A., and Cerione, R. A. (1991) Nature 354, 311-314[CrossRef][Medline] [Order article via Infotrieve]
  22. Margolis, B., Hu, P., Katzav, S., Li, W., Oliver, J. M., Ullrich, A., Weiss, A., and Schlessinger, J. (1992) Nature 356, 71-74[CrossRef][Medline] [Order article via Infotrieve]
  23. Bustelo, X. R., and Barbacid, M. (1992) Science 256, 1196-1199[Medline] [Order article via Infotrieve]
  24. Teramoto, H., Salem, P., Robbins, K. C., Bustelo, X. R., and Gutkind, J. S. (1997) J. Biol. Chem. 272, 10751-10755[Abstract/Free Full Text]
  25. Crespo, P., Schuebel, K. E., Ostrom, A. A., Gutkind, J. S., and Bustelo, X. R. (1997) Nature 385, 169-172[CrossRef][Medline] [Order article via Infotrieve]
  26. Snow, B. E., Antonio, L., Suggs, S., Gutstein, H. B., and Siderovski, D. P. (1997) Biochem. Biophys. Res. Commun. 233, 770-777[CrossRef][Medline] [Order article via Infotrieve]
  27. Fromm, C., Coso, O. A., Montaner, S., Xu, N., and Gutkind, J. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10098-10103[Abstract/Free Full Text]
  28. Coso, O. A., Chiariello, M., Kalinec, G., Kyriakis, J. M., Woodgett, J., and Gutkind, J. S. (1995) J. Biol. Chem. 270, 5620-5624[Abstract/Free Full Text]
  29. Xu, N., Bradley, L., Ambdukar, I., and Gutkind, J. S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6741-6745[Abstract]
  30. Hart, M. J., Sharma, S., elMasry, N., Qiu, R. G., McCabe, P., Polakis, P., and Bollag, G. (1996) J. Biol. Chem. 271, 25452-25458[Abstract/Free Full Text]
  31. Whitehead, I. P., Khosravi-Far, R., Kirk, H., Trigo-Gonzalez, G., Der, C. J., and Kay, R. (1996) J. Biol. Chem. 271, 18643-18550[Abstract/Free Full Text]
  32. Barrett, K., Leptin, M., and Settleman, J. (1997) Cell 91, 905-915[Medline] [Order article via Infotrieve]
  33. Hacker, U., and Perrimon, N. (1998) Genes Dev. 12, 274-84[Abstract/Free Full Text]
  34. Shaw, G. (1996) Bioessays 18, 35-46[Medline] [Order article via Infotrieve]
  35. Fanning, A. S., and Anderson, J. M. (1996) Curr. Biol. 6, 1385-1388[Medline] [Order article via Infotrieve]
  36. Glaven, J. A., Whitehead, I. P., Nomanbhoy, T., Kay, R., and Cerione, R. A. (1996) J. Biol. Chem. 271, 27374-27381[Abstract/Free Full Text]
  37. Teramoto, H., Coso, O. A., Miyata, H., Igishi, T., Miki, T., and Gutkind, J. S. (1996) J. Biol. Chem. 271, 27225-27228[Abstract/Free Full Text]
  38. Paterson, H. F., Self, A. J., Garrett, M. D., Just, I., Aktories, K., and Hall, A. (1990) J. Cell Biol. 111, 1001-1007[Abstract]
  39. Aktories, K., and Hall, A. (1989) Trends Pharmacol. Sci. 10, 415-418[CrossRef][Medline] [Order article via Infotrieve]
  40. Costa, M., Wilson, E. T., and Wieschaus, E. (1994) Cell 76, 1075-1089[Medline] [Order article via Infotrieve]
  41. Parks, S., and Wieschaus, E. (1991) Cell 64, 447-458[Medline] [Order article via Infotrieve]
  42. Xu, N., Voyno-Yasenetskaya, T., and Gutkind, J. S. (1994) Biochem. Biophys. Res. Commun. 201, 603-609[CrossRef][Medline] [Order article via Infotrieve]
  43. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420[CrossRef][Medline] [Order article via Infotrieve]
  44. Hermouet, S., Merendino, J. J., Jr., Gutkind, J. S., and Spiegel, A. M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10455-10459[Abstract]
  45. Kalinec, G., Nazarali, A. J., Hermouet, S., Xu, N., and Gutkind, J. S. (1992) Mol. Cell. Biol. 12, 4687-4693[Abstract]
  46. Srivastava, S. K., Wheelock, R. H., Aaronson, S. A., and Eva, A. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 8868-8872[Abstract]
  47. Habets, G. G., van der Kammen, R. A., Stam, J. C., Michiels, F., and Collard, J. G. (1995) Oncogene 10, 1371-1376[Medline] [Order article via Infotrieve]
  48. Bustelo, X. R. (1996) Crit. Rev. Oncog. 7, 65-88[Medline] [Order article via Infotrieve]
  49. Horii, Y., Beeler, J. F., Sakaguchi, K., Tachibana, M., and Miki, T. (1994) EMBO J. 13, 4776-4786[Abstract]
  50. Bonfini, L., Karlovich, C. A., Dasgupta, C., and Banerjee, U. (1992) Science 255, 603-606[Medline] [Order article via Infotrieve]
  51. Shou, C., Farnsworth, C. L., Neel, B. G., and Feig, L. A. (1992) Nature 358, 351-354[CrossRef][Medline] [Order article via Infotrieve]
  52. Musacchio, A., Gibson, T., Rice, P., Thompson, J., and Saraste, M. (1993) Trends Biochem. Sci. 18, 343-348[CrossRef][Medline] [Order article via Infotrieve]
  53. Lemmon, M. A., Ferguson, K. M., and Schlessinger, J. (1996) Cell 85, 621-624[Medline] [Order article via Infotrieve]
  54. Cho, K. O., Hunt, C. A., and Kennedy, M. B. (1992) Neuron 9, 929-942[Medline] [Order article via Infotrieve]
  55. Michiels, F., Stam, J. C., Hordijk, P. L., van der Kammen, R. A., Ruuls-Van Stalle, L., Feltkamp, C. A., and Collard, J. G. (1997) J. Cell Biol. 137, 387-398[Abstract/Free Full Text]
  56. Berman, D. M., and Gilman, A. G. (1998) J. Biol. Chem. 273, 1269-1272[Free Full Text]
  57. Strathmann, M. P., and Simon, M. I. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5582-5586[Abstract]
  58. Lambright, D. G., Noel, J. P., Hamm, H. E., and Sigler, P. B. (1994) Nature 369, 621-628[CrossRef][Medline] [Order article via Infotrieve]
  59. Gutkind, J. S. (1998) J. Biol. Chem. 273, 1839-1842[Free Full Text]
  60. Birnbaumer, L., and Birnbaumer, M. (1995) J. Recept. Signal Transduct. Res. 15, 213-252[Medline] [Order article via Infotrieve]
  61. Dhanasekaran, N., and Dermott, J. M. (1996) Cell Signal. 8, 235-245[CrossRef][Medline] [Order article via Infotrieve]
  62. Buhl, A. M., Johnson, N. L., Dhanasekaran, N., and Johnson, G. L. (1995) J. Biol. Chem. 270, 24631-24634[Abstract/Free Full Text]
  63. Aragay, A. M., Collins, L. R., Post, G. R., Watson, A. J., Feramisco, J. R., Brown, J. H., and Simon, M. I. (1995) J. Biol. Chem. 270, 20073-20077[Abstract/Free Full Text]
  64. Collins, L. R., Ricketts, W. A., Olefsky, J. M., and Brown, J. H. (1997) Oncogene 15, 595-600[CrossRef][Medline] [Order article via Infotrieve]
  65. Gohla, A., Harhammer, R., and Schultz, G. (1998) J. Biol. Chem. 273, 4653-4659[Abstract/Free Full Text]
  66. Offermanns, S., Laugwitz, K. L., Spicher, K., and Schultz, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 504-508[Abstract]
  67. Hart, M. J., Jiang, X., Kozasa, T., Roscoe, W., Singer, W. D., Gilman, A. G., Sternweis, P. C., and Bollag, G. (1998) Science 280, 2112-2114[Abstract/Free Full Text]
  68. Kozasa, T., Jiang, X., Hart, M. J., Sternweis, P. M., Singer, W. D., Gilman, A. G., Bollag, G., and Sternweis, P. C. (1998) Science 280, 2109-2111[Abstract/Free Full Text]
  69. An, S., Dickens, M. A., Bleu, T., Hallmark, O. G., and Goetzl, E. J. (1997) Biochem. Biophys. Res. Commun. 231, 619-622[CrossRef][Medline] [Order article via Infotrieve]
  70. Hecht, J. H., Weiner, J. A., Post, S. R., and Chun, J. (1996) J. Cell Biol. 135, 1071-1083[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.